Following a pre-Congress press briefing and data presented onsite at ASCO 2025 itself, pharmaphorum spoke with Dr Victoria ...

Merck KGaA (ETR:MRK) has had a rough three months with its share price down 16%. But if you pay close attention, ...

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s ...

Merck, a leading science and technology company, today announced the presentation of detailed results from Cohort B of the global Phase 2 WILLOW study (NCT05162586) evaluating enpatoran, an ...

Merck KGaA’s Rare Tumor Strategy Takes Shape With $3.9B SpringWorks Acquisition SpringWorks Therapeutics brings to Merck KGaA two FDA-approved drugs, both currently under regulatory review in ...

US pharma major Merck & Co has secured a key endorsement for its newly approved respiratory syncytial virus (RSV) prevention ...

The Merck Foundation hosted its 7th Merck Foundation First Ladies Initiative (MFFLI) Summit in Dubai, focusing on enhancing ...

The vote offers a sigh of relief to doctors and public health experts worried about vaccine skepticism creeping into policymaking.

The recommendation for Enflonsia is indicated for respiratory syncytial virus prevention in infants under eight months of age, expanding protection options ahead of the 2025–2026 season.

There’s reason to remain bullish about Merck’s growth prospects in the long run. And at a discounted price, the stock could ...

The summit brought together First Ladies from Africa and Asia to highlight impactful partnerships and share strategies to ...

Merck said that a phase-three study of its pulmonary arterial hypertension treatment met its primary endpoints.